Sep 14, 2010 by Brian Orelli, PhDThis Bad News Could've Been WorseA Seattle Genetics drug fails, but there's more in the pipeline.
Sep 14, 2010 by Brian Orelli, PhD42% Drop? Really? Tell Us Something We Didn't Know.Arena Pharmaceuticals gets knocked down for no good reason.
Sep 10, 2010 by Brian Orelli, PhDA Potential Blockbuster Roars AheadJohnson & Johnson made a good choice to purchase Cougar Biotechnology.
Sep 9, 2010 by Brian Orelli, PhDWill These Drugs Get Past the FDA This Month?See what the FDA has on its decision calendar for the rest of September.
Sep 8, 2010 by Brian Orelli, PhDIs This Drugmaker a Lavish Spender or a Bargain Hunter?Bristol-Myers pays a premium to get a hold of its partner.
Sep 8, 2010 by Brian Orelli, PhDYou Must REALIZE This Drug Works by NowVertex concludes its phase 3 trials with another win.
Sep 2, 2010 by Brian Orelli, PhDFatter Wallet. Up 22%. Still Risky.Orexigen gets a mirror image of Arena's obesity drug deal.
Sep 1, 2010 by Brian Orelli, PhDPipeline Review: Bristol-Myers Squibb's 5 Keys to SuccessHere's its post-Plavix plan.
Aug 31, 2010 by Brian Orelli, PhDA Mostly Meaningless FDA RejectionAstraZeneca heads back to the drawing board.
Aug 31, 2010 by Brian Orelli, PhD5 Drugmakers With Killer DividendsJust be careful; there's a reason they're high.
Aug 31, 2010 by Brian Orelli, PhDDrugmakers May Lose a Back Door for Drug Approval Non-inferiority trials may be inferior.
Aug 30, 2010 by Brian Orelli, PhDMaybe Not a Blockbuster, But We'll Take ItNovartis adds a new blood pressure drug to its offerings.
Aug 30, 2010 by Brian Orelli, PhDPipeline Checkup: Merck Has PotentialThe Schering-Plough acquisition has seemed to help.
Aug 30, 2010 by Brian Orelli, PhDShocker: Sanofi's Interested in GenzymeBut will it come to fruition?
